Posting of Annual Report and confirmation of AGM

RNS Number : 6996A
Omega Diagnostics Group PLC
27 September 2022
 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Posting of Annual Report and confirmation of AGM

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, confirms that the Notice of Annual General Meeting ('AGM') along with the Annual Report and Accounts for the year ended 31 March 2022 has been posted to shareholders yesterday afternoon and will shortly be made available on the Company's website at:

 

https://www.omegadiagnostics.com/Investor-Relations/Corporate-Information/Annual-Report-and-Interim-Results  

 

As previously announced, the AGM of the Company will be held on Wednesday 26 October 2022 at 11.00am at Poets House, St Mary's Street, Ely, CB7 4EY.

 

 

Contacts: 

 

Omega Diagnostics Group PLC 

www.omegadx.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR

Chris Lea, Chief Financial Officer




finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)


Alice Lane/Charlotte Sutcliffe (ECM)




Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus / Sam Allen / Lianne Applegarth

Mob: 07980 541 893 / 07502 558 258 / 07584 391 303

 

About Omega Diagnostics Group PLC

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and specialise in the areas of health and nutrition and global health.

www.omegadx.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSPPUQPBUPPGQQ
UK 100

Latest directors dealings